Current AML cell lines do not predict drug sensitivity because the cell lines harbor strong driver alterations that occur in only a small fraction of patients, and their biology has drifted from that of an AML patient. Leveraging our pipeline for LC-MS/MS, functional testing on patient samples, and innovative data integration, we have created a patient landscape with embedded cell models for prospective therapeutic positioning.

American Association for Cancer Research www.aacr.org